Jazz Pharmaceuticals plc(JAZZ)Stock Analysis
AI analysis on 6,000+ stocks →Deep AI analysis on 6,000+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
JAZZ Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Jazz Pharmaceuticals plc (JAZZ), a Healthcare sector company. JAZZ is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings, Jazz Pharmaceuticals plc reports trailing revenue of $1.1B, net income of $293.1M, free cash flow of $388.5M. Top institutional holders of JAZZ by reported 13-F value include BlackRock,, VANGUARD GROUP, VANGUARD GROUP, based on the most recent SEC filings. JAZZ trades on the Nasdaq exchange and files with the SEC under CIK 1232524. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JAZZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jazz Pharmaceuticals plc directly from SEC EDGAR.
Revenue
Q1 2026
$1.1B
Net Income
Q1 2026
$293.1M
Free Cash Flow
Q1 2026
$388.5M
D/E Ratio
Q1 2026
1.41
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+4.9% YoYNet Income
-163.6% YoYOperating Income
-160.0% YoYEPS (Diluted)
-167.5% YoYTotal Assets
-2.9% YoYTotal Debt
+4.0% YoYOp. Cash Flow
-2.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.27B +4.9% | $4.07B +6.1% | $3.83B +4.8% | $3.66B +18.3% | $3.09B +30.9% | $2.36B |
| Net Income | $-356.1M -163.6% | $560.1M +35.0% | $414.8M +285.1% | $-224.1M +32.0% | $-329.7M -238.2% | $238.6M |
| Operating Income | $-430.2M -160.0% | $716.6M +23.9% | $578.6M +983.0% | $-65.5M -138.5% | $170.3M -55.0% | $378.1M |
| EPS (Diluted) | $-5.84 -167.5% | $8.65 +41.8% | $6.10 +270.4% | $-3.58 +35.1% | $-5.52 -230.8% | $4.22 |
| Total Assets | $11.66B -2.9% | $12.01B +5.4% | $11.39B +5.2% | $10.84B -11.9% | $12.30B +88.2% | $6.54B |
| Total Debt | $6.39B +4.0% | $6.14B -2.8% | $6.32B +9.8% | $5.76B -5.4% | $6.08B +159.7% | $2.34B |
| Operating Cash Flow | $1.36B -2.9% | $1.40B +27.8% | $1.09B -14.1% | $1.27B +63.4% | $778.5M -13.5% | $899.6M |
Track JAZZ with AI-powered research
10 AI analysts debate this stock daily. Free to start.
Available Research
13F Pro tracks comprehensive data for Jazz Pharmaceuticals plc including:
Top Institutional Holders of JAZZ
BlackRock, Inc.
$1.1B5,591,700 shVANGUARD GROUP INC
$1.0B5,917,142 shVANGUARD GROUP INC
$941.8M5,911,765 shBlackRock, Inc.
$926.7M5,451,241 shAmundi
$878.5M6,600,000 shBlackRock Inc.
$851.4M7,069,920 shVANGUARD GROUP INC
$778.5M5,906,945 shVANGUARD GROUP INC
$776.6M6,448,689 shVANGUARD GROUP INC
$764.1M6,211,844 shVANGUARD GROUP INC
$747.1M6,017,403 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $1.1B | 5,591,700 |
| VANGUARD GROUP INC | $1.0B | 5,917,142 |
| VANGUARD GROUP INC | $941.8M | 5,911,765 |
| BlackRock, Inc. | $926.7M | 5,451,241 |
| Amundi | $878.5M | 6,600,000 |
| BlackRock Inc. | $851.4M | 7,069,920 |
| VANGUARD GROUP INC | $778.5M | 5,906,945 |
| VANGUARD GROUP INC | $776.6M | 6,448,689 |
| VANGUARD GROUP INC | $764.1M | 6,211,844 |
| VANGUARD GROUP INC | $747.1M | 6,017,403 |
More Healthcare Companies
View all Healthcare →Unlock Full Research for JAZZ
Get detailed financial analysis, insider activity, institutional flows, AI-powered debates, and quality rankings for Jazz Pharmaceuticals plc and 6,000+ other companies.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is JAZZ a good stock to buy?
13F Pro's AI-powered analysis of Jazz Pharmaceuticals plc (JAZZ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JAZZ are available on the JAZZ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own JAZZ?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JAZZ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Jazz Pharmaceuticals plc's investment landscape.